Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BLFS
stocks logo

BLFS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
24.05M
+5.9%
-0.003
-101.28%
25.62M
+7%
0.020
-300%
27.23M
+7.12%
0.027
-108.08%
Estimates Revision
The market is revising Downward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by -5.34% over the past three months. During the same period, the stock price has changed by -2.38%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.72%
In Past 3 Month
Stock Price
Go Down
down Image
-2.38%
In Past 3 Month
Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 32.29 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 32.29 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.830
sliders
Low
30.00
Averages
32.29
High
34.00
Current: 25.830
sliders
Low
30.00
Averages
32.29
High
34.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$30 -> $32
2025-08-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $32
2025-08-08
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on BioLife Solutions to $32 from $30 and keeps a Buy rating on the shares following the Q2 beat.
Stephens
Stephens
Overweight
initiated
$30
2025-07-21
Reason
Stephens
Stephens
Price Target
$30
2025-07-21
initiated
Overweight
Reason
Stephens resumed coverage of BioLife Solutions with an Overweight rating and $30 price target and named the stock as the analyst's "Best Idea." BioLife is now positioned as more consumable-focused and closely aligned with the cell and gene therapy industry following the sale of SciSafe, CBS, and Stirling, the analyst tells investors. The Media segment "represents a crown jewel asset" as it has about 70% market share and high-60%-plus gross margins, serving as the key growth driver in the near-term, the analyst added.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$27 → $30
2025-03-06
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$27 → $30
2025-03-06
Maintains
Strong Buy
Reason
Northland Capital Markets
Carl Byrnes
Buy
Maintains
$28 → $31
2025-01-08
Reason
Northland Capital Markets
Carl Byrnes
Price Target
$28 → $31
2025-01-08
Maintains
Buy
Reason
Benchmark
Robert Wasserman
Strong Buy
Reiterates
$30
2024-12-19
Reason
Benchmark
Robert Wasserman
Price Target
$30
2024-12-19
Reiterates
Strong Buy
Reason
Keybanc
Paul Knight
Buy
Maintains
$30 → $33
2024-12-13
Reason
Keybanc
Paul Knight
Price Target
$30 → $33
2024-12-13
Maintains
Buy
Reason
KeyBanc raised the firm's price target on BioLife Solutions to $33 from $30 and keeps an Overweight rating on the shares. BioLife, under its new CEO, has completed a quick succession of three asset sales, and the firm's proforma models show a high-growth and high-margin business with its dominance of freeze media for the cell, gene, and CAR-T markets, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioLife Solutions Inc (BLFS.O) is 329.89, compared to its 5-year average forward P/E of -769.36. For a more detailed relative valuation and DCF analysis to assess BioLife Solutions Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-769.36
Current PE
329.89
Overvalued PE
3132.18
Undervalued PE
-4670.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
89.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
202.10
Undervalued EV/EBITDA
-23.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.69
Current PS
0.00
Overvalued PS
12.27
Undervalued PS
5.12
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BLFS News & Events

Events Timeline

(ET)
2025-11-06
16:08:08
BioLife Solutions revises 2025 revenue forecast down to $95M-$96M from previous estimate of $95.5M-$99.0M
select
2025-11-06
16:06:08
BioLife Solutions announces Q3 earnings per share of 1 cent, surpassing consensus of 0 cents.
select
2025-10-07 (ET)
2025-10-07
08:06:10
BioLife Solutions Sells SAVSU Cleo Technologies to Peli BioThermal for $25.5 Million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-24Benzinga
HC Wainwright & Co. Affirms Buy Rating for BioLife Solutions, Keeps $32 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
4.5
11-18NASDAQ.COM
Zacks Industry Outlook Spotlights Boston Scientific, Insulet, BioLife Solutions, and Allurion

  • Industry Challenges: The medical products industry is facing significant challenges, including cost inflation from tariffs, supply-chain delays, and regulatory uncertainties, which are impacting margins and growth outlooks.

  • Resilience Through Innovation: Companies like Boston Scientific, Insulet, BioLife Solutions, and Allurion Technologies are navigating these challenges by focusing on innovation, operational efficiencies, and strategic acquisitions to drive organic growth.

  • Emerging Trends: Key trends shaping the industry include the integration of AI and digital health, a shift towards ambulatory and home-based care, advancements in robotics and specialty therapeutics, and evolving regulatory frameworks that emphasize value-based care.

  • Market Performance: The medical products industry has underperformed compared to the broader market, with a decline of 1.8% over the past year, while companies are still positioned for potential growth through strategic investments and improved operational practices.

[object Object]
Preview
1.0
11-17Newsfilter
BioLife Solutions to Attend Investor Conferences Scheduled for November and December 2025

  • Investor Conferences Participation: BioLife Solutions, Inc. will participate in several investor conferences in November and December 2025, including the Raymond James Napa Small Cap Symposium and the Jefferies Global Healthcare Conference.

  • Corporate Branding Update: The company has released a refreshed corporate branding and an investor presentation, which is available on their website's Investor Relations section.

  • Company Overview: BioLife Solutions specializes in bioproduction products and services for the cell and gene therapy market, aiding in the commercialization of new therapies by ensuring the health and function of biologic materials.

  • Contact Information: For media and investor relations, the Chief Financial Officer, Troy Wichterman, and Alliance Advisors IR, Jody Cain, are available for inquiries.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioLife Solutions Inc (BLFS) stock price today?

The current price of BLFS is 25.83 USD — it has increased 1.25 % in the last trading day.

arrow icon

What is BioLife Solutions Inc (BLFS)'s business?

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

arrow icon

What is the price predicton of BLFS Stock?

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 32.29 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioLife Solutions Inc (BLFS)'s revenue for the last quarter?

BioLife Solutions Inc revenue for the last quarter amounts to 28.07M USD, increased 31.21 % YoY.

arrow icon

What is BioLife Solutions Inc (BLFS)'s earnings per share (EPS) for the last quarter?

BioLife Solutions Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioLife Solutions Inc (BLFS)'s fundamentals?

The market is revising Downward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by -5.34% over the past three months. During the same period, the stock price has changed by -2.38%.
arrow icon

How many employees does BioLife Solutions Inc (BLFS). have?

BioLife Solutions Inc (BLFS) has 159 emplpoyees as of December 05 2025.

arrow icon

What is BioLife Solutions Inc (BLFS) market cap?

Today BLFS has the market capitalization of 1.24B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free